Fujian Green Pine
300132
Yili Chuanning Biotechnology
301301
Shanghai Menon Animal Nutrition Technology
301156
4
Anhui Hyea Aromas
300886
5
Tuoxin Pharmaceutical Group
301089
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 13.47%268.31M | 21.56%971.38M | 23.66%715.09M | 20.68%465.88M | 14.43%236.46M | -14.19%799.11M | -26.10%578.26M | -30.99%386.05M | -18.58%206.64M | -2.01%931.29M |
Operating revenue | 13.47%268.31M | 21.56%971.38M | 23.66%715.09M | 20.68%465.88M | 14.43%236.46M | -14.19%799.11M | -26.10%578.26M | -30.99%386.05M | -18.58%206.64M | -2.01%931.29M |
Other operating revenue | ---- | 151.53%11.78M | ---- | 175.86%5.06M | ---- | -57.52%4.68M | ---- | -61.67%1.83M | ---- | 21.10%11.03M |
Total operating cost | 17.79%238.84M | 24.29%868.46M | 27.88%635.02M | 23.07%402.4M | 18.13%202.77M | -12.08%698.76M | -25.14%496.59M | -30.80%326.98M | -20.24%171.64M | -1.96%794.77M |
Operating cost | 19.38%201.38M | 23.40%716.96M | 26.64%520.96M | 20.13%331.98M | 14.37%168.69M | -16.71%581.01M | -30.04%411.36M | -34.88%276.35M | -23.62%147.49M | -2.39%697.55M |
Operating tax surcharges | -14.75%1.61M | 30.03%7.88M | 43.26%5.63M | 40.35%3.2M | 24.31%1.88M | -24.95%6.06M | -21.20%3.93M | -13.51%2.28M | 54.58%1.52M | 74.51%8.08M |
Operating expense | -12.42%1.46M | 13.18%6.25M | 35.89%4.69M | 33.70%3.07M | 67.78%1.66M | 22.61%5.52M | 6.59%3.45M | 15.45%2.29M | -4.89%990.16K | 19.10%4.51M |
Administration expense | 11.60%23.68M | 26.29%87.11M | 40.53%68.85M | 45.84%44.83M | 75.21%21.22M | 40.26%68.98M | 13.28%48.99M | 19.39%30.74M | 12.20%12.11M | 6.21%49.18M |
Financial expense | 70.01%-880.97K | 2.18%-6.67M | 57.61%-3.31M | 23.33%-5.22M | -1,968.24%-2.94M | -3.13%-6.82M | -20.96%-7.82M | -202.72%-6.81M | -31.70%-142.05K | -1,053.30%-6.61M |
-Interest expense (Financial expense) | 1.75%246.82K | 2.22%1.07M | 48.45%727.03K | 14.19%479.96K | 15.09%242.57K | 1,374.41%1.04M | 592.28%489.76K | 563.05%420.31K | 15,744.28%210.78K | --70.75K |
-Interest Income (Financial expense) | 64.04%-729.22K | -5.29%-6.03M | 2.15%-4.9M | 13.66%-3.24M | -91.37%-2.03M | -136.70%-5.72M | -216.92%-5.01M | -336.02%-3.75M | -178.71%-1.06M | -58.79%-2.42M |
Research and development | -5.41%11.6M | 29.35%56.92M | 4.18%38.21M | 10.96%24.55M | 26.64%12.26M | 4.60%44.01M | 20.68%36.67M | 10.48%22.13M | 3.16%9.68M | 0.47%42.07M |
Credit Impairment Loss | 22.32%-1.48M | -44.09%-2.06M | 109.13%105.55K | 21.51%-1.07M | 19.54%-1.91M | -187.16%-1.43M | -706.63%-1.16M | 35.40%-1.37M | -112.08%-2.37M | 450.76%1.64M |
Asset Impairment Loss | -78.19%-1.62M | -24.68%-1.63M | 24.49%-1.39M | 40.48%-1.14M | -101.19%-907.83K | 31.25%-1.31M | 53.95%-1.84M | 10.87%-1.91M | 70.08%-451.22K | -13.39%-1.9M |
Other net revenue | 12.85%1.56M | -3.42%12.28M | 46.99%10.06M | 179.34%5.13M | 2,032.48%1.38M | 68.61%12.72M | 457.27%6.84M | 215.41%1.84M | 88.01%-71.63K | 12.18%7.54M |
Fair value change income | -44.88%1.17M | -136.85%-1.67M | 32.40%4.67M | 147.67%3.28M | --2.12M | --4.53M | --3.53M | --1.32M | ---- | ---- |
Invest income | 25.64%1.75M | 178.53%14.03M | 122.38%4.12M | 566.92%2.58M | --1.4M | --5.04M | --1.85M | --386.12K | ---- | ---- |
Asset deal income | ---- | 294.82%196.13K | --196.5K | ---- | ---- | --49.67K | ---- | ---- | ---- | ---- |
Other revenue | 154.07%1.74M | -41.62%3.41M | -47.15%2.36M | -56.45%1.48M | -75.10%684.61K | -25.27%5.83M | -11.45%4.46M | 27.45%3.4M | 35.56%2.75M | -11.92%7.8M |
Operating profit | -11.51%31.03M | 1.88%115.2M | 1.82%90.13M | 12.63%68.6M | 0.42%35.07M | -21.51%113.07M | -26.44%88.52M | -28.60%60.91M | -8.15%34.92M | -1.65%144.06M |
Add:Non operating Income | -81.08%100 | 215.39%4.1K | 583.12%4.1K | 82.48%1.09K | 32.11%528.45 | -99.84%1.3K | -99.93%600 | -99.93%600 | --400 | -51.06%837.85K |
Less:Non operating expense | 130.90%248.06K | -44.47%140.7K | 445.92%140.38K | 1,292.42%110.48K | 2,955.07%107.43K | 513.00%253.38K | -27.30%25.71K | -77.57%7.93K | -2.90%3.52K | 18.07%41.34K |
Total profit | -11.95%30.79M | 1.99%115.06M | 1.69%89.99M | 12.46%68.49M | 0.12%34.97M | -22.12%112.82M | -26.95%88.5M | -29.27%60.9M | -8.15%34.92M | -2.23%144.86M |
Less:Income tax cost | -22.43%2.63M | 2.88%12.05M | -18.87%6.1M | 4.03%6.02M | -14.08%3.39M | -11.51%11.71M | -34.24%7.52M | -28.68%5.79M | -9.30%3.95M | -20.67%13.23M |
Net profit | -10.82%28.15M | 1.89%103.02M | 3.60%83.89M | 13.35%62.47M | 1.94%31.57M | -23.18%101.11M | -26.19%80.97M | -29.33%55.11M | -8.00%30.97M | 0.11%131.63M |
Net profit from continuing operation | -10.82%28.15M | 1.89%103.02M | 3.60%83.89M | 13.35%62.47M | 1.94%31.57M | -23.18%101.11M | -26.19%80.97M | -29.33%55.11M | -8.00%30.97M | 0.11%131.63M |
Net profit of parent company owners | -10.82%28.15M | 1.89%103.02M | 3.60%83.89M | 13.35%62.47M | 1.94%31.57M | -23.18%101.11M | -26.19%80.97M | -29.33%55.11M | -8.00%30.97M | 0.22%131.63M |
Earning per share | ||||||||||
Basic earning per share | -10.71%0.25 | -6.25%0.9 | -6.33%0.74 | -1.79%0.55 | -24.32%0.28 | -38.85%0.96 | -39.69%0.79 | -39.78%0.56 | -7.50%0.37 | 0.64%1.57 |
Diluted earning per share | -10.71%0.25 | -6.25%0.9 | -6.33%0.74 | -1.79%0.55 | -24.32%0.28 | -38.85%0.96 | -39.69%0.79 | -39.78%0.56 | -7.50%0.37 | 0.64%1.57 |
Other composite income | 85.68%-134.27K | 1,259.56%2.22M | 1,103.59%5.03M | -1,219.90%-891.95K | -553.90%-937.67K | -14.33%162.96K | -500.82K | 79.65K | -143.4K | 190.21K |
Other composite income of parent company owners | 85.68%-134.27K | 1,259.56%2.22M | 1,103.59%5.03M | -1,219.90%-891.95K | -553.90%-937.67K | -14.33%162.96K | ---500.82K | --79.65K | ---143.4K | --190.21K |
Total composite income | -8.53%28.02M | 3.91%105.23M | 10.49%88.92M | 11.57%61.58M | -0.63%30.63M | -23.17%101.27M | -26.64%80.47M | -29.23%55.19M | -8.42%30.83M | 0.26%131.82M |
Total composite income of parent company owners | -8.53%28.02M | 3.91%105.23M | 10.49%88.92M | 11.57%61.58M | -0.63%30.63M | -23.17%101.27M | -26.64%80.47M | -29.23%55.19M | -8.42%30.83M | 0.37%131.82M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
Auditor | -- | Beijing Dehao International Accounting Firm (Special General Partnership) | -- | -- | -- | Dahua Certified Public Accountants (Special General Partnership) | -- | -- | -- | Dahua Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.